Caprion Signs Biomarker ID Deal with Boehringer Ingelheim | GenomeWeb

NEW YORK, July 12 (GenomeWeb News) - Caprion Pharmaceuticals said today that it has entered into a research collaboration with Boehringer Ingelheim to identify metabolic and inflammatory disease biomarkers using Caprion's CellCarta proteomics discovery platform.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.